Tumor Relapsed Study of Serum Trxr Activity in Advanced Non-small Cell Lung Cancer

NCT01980212 | Completed

• 1 other identifier: TRSTILC
• Study Type: observational
• Target: 500
• Locations: 1 country
• Sites: 1

Brief Summary

In pre-clinical study we found that the thioredoxin reductase activity of serum harbours huge difference between cancer patients and non-cancer patients, the enzyme activity elevated remarkably among cancer patients, and after any kind of treatment serum thioredoxin reductase activity declined remarkably, so we hypothesis that serum thioredoxin reductase activity could be a warning marker for early progression of first-line treatment for advanced non-small cell lung cancer

Conditions

Advanced Non-small Cell Lung Cancer; First Line Treatment; Thioredoxin Reductase Activity; Carcinoembryonic Antigen; Progression

Keywords

non-small cell lung cancer; thioredoxin reductase

Outcome Measures

Primary Outcomes (1)

• To measure the thioredoxin reductase activity in blood

  3-4 ml whole blood was obtained and then centrifuged and stored at -20 ℃, thioredoxin reductase activity was measured within 30 days using 5，5'-Dithio bis-（2-nitrobenzoic acid）(DTNB) method.

  may 2013 - may 2014 (1 year)

Secondary Outcomes (1)

• To measure the carcinoembryonic antigen (CEA) level in blood

  may 2013- may 2014 (1 year)

Study Arms (1)

first line advanced non-small cell lung cancer

patients newly diagnosed advanced non-small cell lung cancer, and received platinum based chemotherapy in Hunan Province Tumor Hospital

Eligibility Criteria

• Age: 18 Years - 80 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients diagnosed with non-small lung cancer and receiving platinum based first-line chemotherapy in Medical Oncology Department of Affiliated Cancer Hospital of Xiangya School of Medicine Central South University/Hunan Province Tumor Hospital

You may qualify if:

• Pathologically proven non-small cell lung cancer, stage Ⅳ patients or unsuitable for local treatment of ⅢB stage patients
• Malignant tumor treatment naive including surgery（except for surgery for cervical cancer and cutaneous squamous cell carcinoma 5 years before, except for lung cancer patients who received surgery and adjuvant chemotherapy after 12 month then diagnosed with stage ⅢB or Ⅳ）
• Signed informed consent would like to provide blood for research

You may not qualify if:

• Patients received antitumor treatment before
• Patients with contraindication of chemotherapy
• Pregnant or breast feeding women

Sponsors & Collaborators

• Hunan Province Tumor Hospital: lead

Study Sites (1)

Hunan Provincal Tumor Hospital

Changsha, Hunan, 410013, China

Location

Biospecimen

Retention: SAMPLES WITH DNA

3-4 ml whole blood was obtained and then centrifuged and stored at -20 ℃

MeSH Terms

Conditions

Disease Progression; Carcinoma, Non-Small-Cell Lung

Condition Hierarchy (Ancestors)

Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Carcinoma, Bronchogenic; Bronchial Neoplasms; Lung Neoplasms; Respiratory Tract Neoplasms; Thoracic Neoplasms; Neoplasms by Site; Neoplasms; Lung Diseases; Respiratory Tract Diseases

Study Officials

• Nong Yang, MD

  Hunan Province Tumor Hospital

  STUDY CHAIR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: chief

Study Record Dates

• First Submitted: November 4, 2013
• First Posted: November 8, 2013
• Study Start: May 1, 2013
• Primary Completion: December 1, 2016
• Study Completion: December 1, 2018
• Last Updated: March 26, 2020

Record last verified: 2020-03

Locations

CN (1)